315 related articles for article (PubMed ID: 22943933)
21. Mirabegron: a safety review.
Tyagi P; Tyagi V; Chancellor M
Expert Opin Drug Saf; 2011 Mar; 10(2):287-94. PubMed ID: 21142693
[TBL] [Abstract][Full Text] [Related]
22. Safety and Effectiveness of Mirabegron in Patients with Overactive Bladder in a Real-World Clinical Setting: A Japanese Post-Marketing Study.
Nozawa Y; Kato D; Tabuchi H; Kuroishi K
Low Urin Tract Symptoms; 2018 May; 10(2):122-130. PubMed ID: 27860325
[TBL] [Abstract][Full Text] [Related]
23. Proarrhythmic safety of repeat doses of mirabegron in healthy subjects: a randomized, double-blind, placebo-, and active-controlled thorough QT study.
Malik M; van Gelderen EM; Lee JH; Kowalski DL; Yen M; Goldwater R; Mujais SK; Schaddelee MP; de Koning P; Kaibara A; Moy SS; Keirns JJ
Clin Pharmacol Ther; 2012 Dec; 92(6):696-706. PubMed ID: 23149929
[TBL] [Abstract][Full Text] [Related]
24. Mirabegron the first β3-adrenoceptor agonist for overactive bladder (OAB): a summary of the phase III studies.
Chapple C
BJU Int; 2014 Jun; 113(6):847-8. PubMed ID: 24905658
[No Abstract] [Full Text] [Related]
25. Single-dose bioavailability of levetiracetam intravenous infusion relative to oral tablets and multiple-dose pharmacokinetics and tolerability of levetiracetam intravenous infusion compared with placebo in healthy subjects.
Ramael S; De Smedt F; Toublanc N; Otoul C; Boulanger P; Riethuisen JM; Stockis A
Clin Ther; 2006 May; 28(5):734-44. PubMed ID: 16861095
[TBL] [Abstract][Full Text] [Related]
26. Intestinal absorption mechanism of mirabegron, a potent and selective β₃-adrenoceptor agonist: involvement of human efflux and/or influx transport systems.
Takusagawa S; Ushigome F; Nemoto H; Takahashi Y; Li Q; Kerbusch V; Miyashita A; Iwatsubo T; Usui T
Mol Pharm; 2013 May; 10(5):1783-94. PubMed ID: 23560393
[TBL] [Abstract][Full Text] [Related]
27. A randomized controlled study of the efficacy of tamsulosin monotherapy and its combination with mirabegron for overactive bladder induced by benign prostatic obstruction.
Ichihara K; Masumori N; Fukuta F; Tsukamoto T; Iwasawa A; Tanaka Y
J Urol; 2015 Mar; 193(3):921-6. PubMed ID: 25254938
[TBL] [Abstract][Full Text] [Related]
28. Profile of mirabegron in the treatment of overactive bladder: place in therapy.
Sharaf A; Hashim H
Drug Des Devel Ther; 2017; 11():463-467. PubMed ID: 28255232
[TBL] [Abstract][Full Text] [Related]
29. An Exploratory Study in Healthy Male Subjects of the Mechanism of Mirabegron-Induced Cardiovascular Effects.
van Gelderen M; Stölzel M; Meijer J; Kerbusch V; Collins C; Korstanje C
J Clin Pharmacol; 2017 Dec; 57(12):1534-1544. PubMed ID: 28618007
[TBL] [Abstract][Full Text] [Related]
30. Mirabegron (Myrbetriq) for overactive bladder.
Med Lett Drugs Ther; 2013 Feb; 55(1410):13-5. PubMed ID: 23459457
[No Abstract] [Full Text] [Related]
31. Dual Therapy for Refractory Overactive Bladder in Children: A Prospective Open-Label Study.
Morin F; Blais AS; Nadeau G; Moore K; Genois L; Bolduc S
J Urol; 2017 Apr; 197(4):1158-1163. PubMed ID: 27914999
[TBL] [Abstract][Full Text] [Related]
32. Results of a randomized phase III trial of mirabegron in patients with overactive bladder.
Nitti VW; Auerbach S; Martin N; Calhoun A; Lee M; Herschorn S
J Urol; 2013 Apr; 189(4):1388-95. PubMed ID: 23079373
[TBL] [Abstract][Full Text] [Related]
33. Pharmacokinetic drug interaction study between overactive bladder drugs mirabegron and tolterodine in Japanese healthy postmenopausal females.
Nomura Y; Iitsuka H; Toyoshima J; Kuroishi K; Hatta T; Kaibara A; Katashima M; Moy S; Sawamoto T
Drug Metab Pharmacokinet; 2016 Dec; 31(6):411-416. PubMed ID: 27829538
[TBL] [Abstract][Full Text] [Related]
34. Safety and effectiveness of mirabegron in patients with overactive bladder aged ≥75 years: Analysis of a Japanese post-marketing study.
Yoshida M; Nozawa Y; Kato D; Tabuchi H; Kuroishi K
Low Urin Tract Symptoms; 2019 Jan; 11(1):30-38. PubMed ID: 28901041
[TBL] [Abstract][Full Text] [Related]
35. Pharmacokinetics and disposition of the oxytocin receptor antagonist L-368,899 in rats and dogs.
Thompson KL; Vincent SH; Miller RR; Colletti AE; Alvaro RF; Wallace MA; Feeney WP; Chiu SH
Drug Metab Dispos; 1997 Oct; 25(10):1113-8. PubMed ID: 9321512
[TBL] [Abstract][Full Text] [Related]
36. A single-dose, three-period, six-sequence crossover study comparing the bioavailability of solution, suspension, and enteric-coated tablets of magnesium valproate in healthy Mexican volunteers under fasting conditions.
Marcelín-Jiménez G; Angeles-Moreno AP; Contreras-Zavala L; Morales-Martínez M; Rivera-Espinosa L
Clin Ther; 2009 Sep; 31(9):2002-11. PubMed ID: 19843490
[TBL] [Abstract][Full Text] [Related]
37. Drug therapy for an overactive bladder.
Thiagamoorthy G; Cardozo L; Srikrishna S
Womens Health (Lond); 2015 Jul; 11(4):445-8. PubMed ID: 26238677
[No Abstract] [Full Text] [Related]
38. Effects of mirabegron, a novel β3-adrenoceptor agonist, on primary bladder afferent activity and bladder microcontractions in rats compared with the effects of oxybutynin.
Aizawa N; Homma Y; Igawa Y
Eur Urol; 2012 Dec; 62(6):1165-73. PubMed ID: 22981677
[TBL] [Abstract][Full Text] [Related]
39. Pharmacokinetics and bioavailability of sulfadiazine and trimethoprim following intravenous, intramuscular and oral administration in ostriches (Struthio camelus).
Abu-Basha EA; Gehring R; Hantash TM; Al-Shunnaq AF; Idkaidek NM
J Vet Pharmacol Ther; 2009 Jun; 32(3):258-63. PubMed ID: 19646090
[TBL] [Abstract][Full Text] [Related]
40. Selective β₃-adrenoceptor agonists for the treatment of overactive bladder.
Andersson KE; Martin N; Nitti V
J Urol; 2013 Oct; 190(4):1173-80. PubMed ID: 23458471
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]